29 December 2016

VERONA PHARMA PLC - Issue of Equity

PR Newswire

Verona Pharma plc

(“Verona Pharma” or the “Company”)

Exercise of Options

Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has issued 2,000,000 new ordinary shares in the capital of the Company (the “New Shares”) following an exercise of share options by a former employee. Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM, with dealings expected to commence on 6 January 2017 (“Admission”).

Following Admission, the Company will have a total of 2,568,053,160 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 2,568,053,160 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

 Verona Pharma plc Tel: +44 (0)20 3283 4200
 Jan-Anders Karlsson, Chief Executive Officer  
   
 N+1 Singer (Nominated Adviser and Broker) Tel: +44 (0)20 7496 3000
 Aubrey Powell/James White  
   
 FTI Consulting Tel: +44 (0)20 3727 1000
 Simon Conway/Stephanie Cuthbert/Natalie Garland-Collins
 
 

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us